Lucida Medical Raises £8.7 Million for AI-Driven Prostate Cancer Diagnosis
Lucida Medical, a Cambridge-based company specializing in AI software for analyzing MRI scans, has successfully raised £8.7 million in its latest funding round. The company focuses on developing AI tools that assist in diagnosing prostate cancer with high accuracy. This round was led by IW Capital, with participation from XTX Ventures.
Company Background
Lucida Medical's AI software, known as Pi, is designed to perform expert-level analysis of MRI scans to aid in the diagnosis of prostate cancer. According to co-founder and CEO Antony Rix, the goal is to provide clinicians with the ability to make faster, more confident decisions while minimizing unnecessary interventions for patients. "Cancer imaging volumes are rising rapidly but reporting capacity is not keeping pace," Rix said. "Our goal is to give clinicians faster, more confident decisions while reducing unnecessary interventions for patients."
Funding Details
The funding round, which took place on March 30, 2026, was led by IW Capital. XTX Ventures also participated in this round, providing additional financial backing. This investment will enable Lucida Medical to expand its reach within the NHS, where its diagnostic service is already being utilized.
Use of Funds
The newly secured funds will be used to accelerate the deployment of Lucida Medical's AI diagnostic tools across more NHS pathways. This expansion is aimed at reducing the burden on healthcare providers by facilitating quicker and more accurate diagnoses. The funds are expected to help the company enhance its technology and potentially expand its applications beyond prostate cancer diagnosis.
Leadership Team
Lucida Medical was co-founded by Antony Rix, who serves as the CEO, and Evis Sala. Both founders bring significant expertise to the company, which has positioned itself as a key player in the AI-driven medical diagnostics field.
Conclusion
With the successful closure of this funding round, Lucida Medical is poised to make significant advancements in the field of prostate cancer diagnosis. The support from investors like IW Capital and XTX Ventures underscores the growing interest in AI technologies that can improve healthcare outcomes. As the company continues to innovate, it aims to reduce wait times and improve diagnostic accuracy for patients across the UK.